24.29
Hims Hers Health Inc stock is traded at $24.29, with a volume of 41.99M.
It is up +13.72% in the last 24 hours and down -1.94% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$21.36
Open:
$21.72
24h Volume:
41.99M
Relative Volume:
1.25
Market Cap:
$5.54B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
46.52
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+25.27%
1M Performance:
-1.94%
6M Performance:
-61.30%
1Y Performance:
-17.55%
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
24.29 | 4.87B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Applauding FDA's Move Towards Regulatory Clarity on Peptide Therapy - Hims & Hers Newsroom
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides - Seeking Alpha
Hims & Hers Health stock gains as ZAVA and Livewell acquisitions boost international sales - Traders Union
Why is Hims & Hers Health stock up today? - Traders Union
Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes - Seeking Alpha
Hims Didn't Protect Customer Data From Hackers, Suit Says - Law360
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms - The Globe and Mail
Modest gains for Hims & Hers Health stock as $21.38 resistance remains in focus - Traders Union
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims & Hers Health Inc (HIMS) Shares Surge 8.8% -- What GF Score of 76 Tells Investors - GuruFocus
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026 - The Joplin Globe
Hims & Hers schedules May 11 earnings release, 5 p.m. ET call - Stock Titan
Hims & Hers Health (HIMS) jumps 9.8% as GLP-1 partnership momentum returns to focus - Quiver Quantitative
Hims & Hers Health stock rises as sellers remain in control of the short-term trend - Traders Union
Okta breach chain hits Hims & Hers in wider ShinyHunters attack spree - Cybernews
Why Hims & Hers Health, Inc. (HIMS) Surged On Friday - MSN
Hims & Hers Health, Inc. Class A Trade Ideas — LS:A2QMYY - TradingView
A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot - Yahoo Finance
Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan - Yahoo Finance
Hims & Hers (NYSE: HIMS) CEO makes 845,866-share bona fide gift - Stock Titan
HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce - Stocktwits
Hims Breach Exposes the Most Sensitive Kinds of PHI - Dark Reading
Hims & Hers Health stock price forecast: $21.38 resistance in focus as HIMS drops 1.87% - Traders Union
Why Is HIMS Stock Down 40%? - Trefis
Did Hims & Hers Just Become an AI Company? - The Globe and Mail
Liquidity Mapping Around (HIMS) Price Events - Stock Traders Daily
Investor relations - HIMS Investor Relations
2 Profitable Stocks with Exciting Potential and 1 We Ignore - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health - The National Law Review
Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure - MEXC
Why Is HIMS Stock Slipping Premarket Today? - Stocktwits
Hims & Hers (HIMS) Stock Down 39% as GLP-1 Brand Transition Squeezes Margins - CoinCentral
Hims & Hers’ Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off? - TipRanks
Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration - Sahm
Hims & Hers Health stock rises as FDA-approved Wegovy and Ozempic come back to market - Traders Union
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Hims & Hers Health Is No Longer What The Market Thinks (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. Jumps 5.5% Amid Sector-Wide Selling - AlphaStreet
BofA cuts Hims and Hers stock price target on EBITDA concerns - Investing.com
Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path - Sahm
Hims & Hers Health, Inc. (HIMS) Shares Decline as Broader Market Advances: Important Details - Bitget
Okupe, Hims & Hers health CFO, sells $79k in shares - Investing.com India
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Hims & Hers Faces Legal Scrutiny as Novo Nordisk Partnership Ends - timothysykes.com
Hims & Hers Faces Legal Scrutiny After Novo Nordisk Ends Partnership - timothysykes.com
Hackers access names, contact information of some Hims customers - Modern Healthcare
Hims & Hers Health stock falls as insider files to sell shares - Investing.com
Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss MembershipHas The Bull Case Changed? - Yahoo Finance
3 Sectors to Buy While They’re Down and 1 to Walk Away From - Investing.com
Hims & Hers Health and Fortune Brands Innovation have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
3 Sectors to Buy While They're Down and 1 to Walk Away From - MarketBeat
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):